| 摘要 |
A recombinant adenovirus which is a gene delivery system having improved tumor-specific expression ability is provided to ensure anti-tumor effect under the hypoxia condition and enhance the stability in the body. A gene delivery system having improved tumor-specific expression ability comprises: a control sequence of gene expression containing a HRE (hypoxia-responsive element) enhancer sequence and hTERT (human telomere reverse transcriptase) on the downstream of the HRE sequence, and a gene sequence which is operatively linked to the regulatory sequence. The gene delivery system is a plasmid, recombinant adenovirus, adeno-associated viruses (AAV), retrovirus, lentivirus, herpes simplex virus, vaccinia virus, liposome or niosome. A recombinant adenovirus having improved cancer cell-specific cytotoxicity comprises: an ITR (inverted terminal repeat) sequence of adenovirus; the regulatory sequence; and the gene sequence which is operatively linked to the regulatory sequence. A pharmaceutical composition for anti-tumor comprises therapeutically effective amount of the recombinant adenovirus and pharmaceutically acceptable carrier.
|
